Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Massachusetts Medical School
Headquarters: Worcester, MA, United States of America
Website: http://www.umassmed.edu
Year Founded: 1962
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Mar 26, 2024
Distillery Therapeutics
Inhibition for TRPC6 for triple negative breast cancer
BioCentury | Nov 16, 2023
Discovery & Translation
Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 27, 2023
Discovery & Translation
Targeting ACSS2 in solid tumors; plus a multi-lab preclinical trial and more
BioCentury’s roundup of translational innovation
BioCentury | Jan 31, 2023
Distillery Therapeutics
ACVR1 gene replacement for heterotopic ossification in FOP
BioCentury | Oct 3, 2022
Deals
Quick exit for Medicxi as Incyte buys vitiligo company Villaris
Incyte pays $70M up front to add UMass spinout’s vitiligo candidate, complementing topical ruxolitinib
BioCentury | Apr 6, 2022
Data Byte
Wave next up in the C9orf72 pipeline
Four other therapies in preclinical development for ALS or FTD
Items per page:
1 - 10 of 212